Monday, 20 May 2019

Breckenridge announces approval of Hep B virus tablets

02 April 2018 | News

The product is manufactured by RA Chem Pharma Limited and supplied to Breckenridge for exclusive distribution in the United States.

 

Singapore – Breckenridge Pharmaceutical announced that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Entecavir tablets USP, 0.5mg and 1mg, a generic version of Baraclude Tablets by Bristol-Myers Squibb Company.  The product, which was developed in collaboration with Welding GMBH & Co., is manufactured by RA Chem Pharma Limited and supplied to Breckenridge for exclusive distribution in the United States.  Breckenridge will launch the product immediately. 

Entecavir tablets (Baraclude) are a Hepatitis B virus nucleoside analog reverse transciptase inhibitor for the treatment of chronic hepatitis B virus infection in adults and children at least 2 year of age.  Baraclude generated combined annual sales of $95.9M, according to MAT January 2018 IQVIA sales data.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls